Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

to support the planned parallel,

confirmatory U.S. Phase IIb clinical trial for this indication.

-- Financing

-- Completed a private placement financing on December 19, 2007 for

gross proceeds of $16,867,200.

-- Completed a private placement financing on October 2, 2008 for gross

proceeds of $11,424,000.

-- Other

-- Appointed W. Thomas Hodgson to the Board of Directors.

-- Subsequent to the year-end, Lumera Corporation gave notice to its

termination of the biochip sub-license agreement, to be effective

December 19, 2008.

For fiscal 2008, the Company recorded a net loss of $6,964,000, which represents a decrease of $710,000 when compared to fiscal 2007. The net loss per common share for fiscal 2008 was $0.16 and represents a decrease of $0.06 in loss per common share when compared to fiscal 2007.

Product revenue along with license fees and royalties contributed to the increase in revenue in fiscal 2008 when compared to fiscal 2007 while research and development contract revenue were nil in fiscal 2008 and therefore lower than fiscal 2007.

Overall expenses in fiscal 2008 were lower than in fiscal 2007. Higher interest income and foreign exchange gains in fiscal 2008 offset higher research and development expenditures and operating, general and administrative expenditures and a one time write down of intangible assets in fiscal 2007.

FINANCIAL REVIEW

Total revenues in fiscal 2008 were $3,591,000 and represent an increase of $167,000 or 4.9% when compared to total revenues in fiscal 2007 of $3,424,000. Product revenue along with license fees and royalties contributed to the increase in revenue in fiscal 2008 when compared to fiscal 2007 while research and development contract revenue were nil in fiscal 2008 and therefore lower than fiscal 2007.

Product revenue in fiscal 2008 totaled $2,952,000 and repre
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 An increase of awareness related ... forms of food nutrients, regulatory changes and concerns related ... in demand for natural astaxanthin over the past few ... up their capacities to satisfy the rising demand. ... source astaxanthin (used in nutraceuticals, aqua feed, food and ...
(Date:3/25/2015)... Having added two International locations in ... 2014, ITRA Global proudly announced recently the organization’s expansion ... Alliance, based in the United States, is one of ... of commercial real estate. , Saltwood International ... that exclusively advises occupiers of office space, ensuring that ...
(Date:3/25/2015)... March 25, 2015  The Technology Association of ... dedicated to the promotion and economic advancement of ... Health as one of its Top 40 Innovative Technology ... recognize this prestigious group at the 2015 Georgia Technology ... Galleria Centre. TAG,S Top 40 Awards recognize ...
(Date:3/25/2015)... , March 25, 2015 ... today version 4 of Face2Gene, allowing geneticists ... from computers, as well as mobile devices. Face2Gene® facilitates ... human malformations to present comprehensive and up-to-date genetic references. ... Clinical Genetics Meeting, ACMG 2015, in Salt ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2International Organization Expands its Global Reach to Warsaw, Poland 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... Lines for Assay Development, Biomarker Identification ... and ADME/Tox ... Bulletin Board: MCET), entered into a worldwide,exclusive license and technology ... Fa2N-4 immortalized,adult human liver cell lines. Corning paid MultiCell ...
... protection ... Fla., Oct. 10 Union Springs Pharmaceuticals,LLC, announced today at ... product, MyClyns(TM). MyClyns is the first product of its,kind to ... in the field when exposed to harmful pathogens. The product, ...
... DermTech International, Inc.,a biotechnology company developing ... melanoma and other diseases, today appointed John ... Dr. Quackenbush is a,Professor of Biostatistics and ... Professor of Computational Biology and Bioinformatics,at the ...
Cached Biology Technology:MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3MyClyns(TM), a New Standard of Personal Protection, is Announced at the EMS and Firehouse Central EXPO 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... took place in Florence last week. It provided us with some ... Did life begin on Mars rather than on earth?, ... "Terror Bird", was probably a herbivore Goldschmidt2014 is ... June, 2014, so if you want to attend, put the dates ...
... estimate that there is a minimum of 320,000 viruses in ... a majority of them, they say, could provide information critical ... This undertaking would cost approximately $6.3 billion, or $1.4 billion ... fraction of the economic impact of a major pandemic like ...
... Candida albicans is a common fungus found living in, ... species causes no harm to humans unless it can breach ... or death. It is known as an opportunistic pathogen that ... New research, presented today at the Society for General Microbiology,s ...
Cached Biology News:First estimate of total viruses in mammals 2First estimate of total viruses in mammals 3First estimate of total viruses in mammals 4Research identifies how mouth cells resist Candida infection 2
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: